MedTrace Logo

Physical and Chemical Study of Atherosclerosis Mechanisms

NCT01700075 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2012-10-04

No results posted yet for this study

Summary

Study the mechanisms of atherosclerosis based on a comparative study of physical and chemical properties of lipid tissues at various localization with subsequent development of concept of treatment and prevention.

Conditions

  • Myocardial Infarction
  • Coronary Artery Diseases
  • Diabetes Mellitus, Type 2
  • Atherosclerosis of Femoral Artery

Interventions

DRUG

Conventional treatment

Lipidlowering: "Atorvastatin" (Liprimar) - 40mg per day. Antihypertensive: "Diroton" (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and "Ditiazem" (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day. Antihyperglycemic drugs: biguanides "Metformin" - 0.5 g two or tree times per day, or "Exenatide" - 5-10 µg per day. Anti-inflammatory: "TromboACC" (acetylsalicylate acid) up to 2 g per day and/or "Clopidogrel" (thienopyridine class antiplatelet agent) - 75mg per day.

DIETARY_SUPPLEMENT

Weight loss treatment

Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.

Sponsors & Collaborators

  • Ministry of Health, Kazakhstan

    collaborator OTHER_GOV

  • Nazarbayev University

    lead OTHER

Principal Investigators

  • Kuat P Oshakbayev, MD, PhD, DsC · Scientisic research institute of cardiology and internal diseases

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
26 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-12-31
Completion
2011-12-31

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01700075 on ClinicalTrials.gov